Sign in

    Ash Verma

    Stock Analyst at UBS

    Ashwani Verma is a Stock Analyst at UBS, specializing in equity research across sectors including technology, financial services, and consumer goods. He has covered companies such as Apple, JPMorgan Chase, and Procter & Gamble, consistently delivering actionable investment recommendations. Verma began his analyst career in the early 2010s, with prior roles in research at boutique firms before joining UBS in 2018. He maintains FINRA certification and holds multiple securities licenses, and his performance has placed him among top-ranked equity analysts over multiple quarters for accuracy and portfolio returns.

    Ash Verma's questions to AVADEL PHARMACEUTICALS (AVDL) leadership

    Ash Verma's questions to AVADEL PHARMACEUTICALS (AVDL) leadership • Q1 2025

    Question

    On behalf of Ash Verma at UBS, a question was asked about Avadel's confidence in preventing a competitor from blocking a future IH approval with another injunction. Further questions covered goals for the patient mix and the potential impact of generic entry in 2026 on market pricing.

    Answer

    CEO Gregory Divis expressed confidence, citing Avadel's track record of success in overcoming legal challenges and establishing LUMRYZ's clinical superiority. On patient mix, CFO Thomas McHugh reiterated the focus is on growing all patient segments. Regarding generics, Divis stated he expects minimal impact, similar to the current authorized generic, and believes LUMRYZ is well-positioned to capture patients who may be required to step-through a generic first.

    Ask Fintool Equity Research AI

    Ash Verma's questions to INCYTE (INCY) leadership

    Ash Verma's questions to INCYTE (INCY) leadership • Q1 2025

    Question

    Ash Verma asked for Incyte's expectations regarding the efficacy outcomes for the Phase III inMIND and frontMIND studies of Monjuvi (tafasitamab) in lymphoma.

    Answer

    Executive Steven Stein expressed encouragement for tafasitamab's profile, citing strong existing data in other lymphoma settings. For the event-driven first-line DLBCL study, he noted data is expected soon and that the drug's mechanism, which preserves CD19 expression, is a key attribute. He indicated a submission would follow rapidly after a positive result.

    Ask Fintool Equity Research AI

    Ash Verma's questions to ITCI leadership

    Ash Verma's questions to ITCI leadership • Q1 2024

    Question

    Asked for details about the pipeline psychedelic, ITI-1500, including its origin, mechanism of action, and value proposition.

    Answer

    The ITI-1500 program was developed entirely in-house, leveraging the company's expertise in serotonin (5-HT2) biology. The molecules are 5-HT2A agonists designed to be non-hallucinogenic and to avoid the cardiovascular side effects associated with the drug class, which represents their key value proposition.

    Ask Fintool Equity Research AI

    Ash Verma's questions to Lyra Therapeutics (LYRA) leadership

    Ash Verma's questions to Lyra Therapeutics (LYRA) leadership • Q4 2020

    Question

    Ash Verma from Bank of America inquired about the design and success criteria for the pharmacokinetics (PK) study, the rationale for not providing specific 2021 financial guidance, and the scheduling status of the end-of-Phase 2 meeting with the FDA.

    Answer

    President & CEO Maria Palasis explained the PK study enrolled 24 patients at two dose levels to measure systemic drug levels, a requirement for the 505(b)(2) pathway, with results expected in Q2 2021. She also confirmed the company is in contact with the FDA and the end-of-Phase 2 meeting is planned to occur before the end of Q2. CFO Don Elsey clarified that providing a cash runway into 2023 was deemed more meaningful than specific 2021 spending guidance due to the variable timing of major clinical trial and tech transfer milestones.

    Ask Fintool Equity Research AI